Patent · US Active

Antagonists of human integrin (α4)(β7)

US11174228B2 · kind B2 · utility

1Cited by

15References

20Claims

0Family size

Assignee

Morphic Therapeutic, Inc. · US

Inventors

Matthew G. Bursavich · Tuckahoe, US
Dawn M. Troast · Bedford, US
Bryce A. Harrison · Framingham, US
Blaise S. Lippa · Newton, US
Bruce N. Rogers · Belmont, US
Kyle D. Konze · New York, US
Aleksey I. Gerasyuto · Flemington, US
Tyler Day · New York, US
Fu-Yang Lin · Sudbury, US
Kristopher N. Hahn · Medford, US
Mats A. Svensson · New York, US
Byungchan Kim · West New York, US
Cheng Zhong · Belmont, US
Alexey A. Lugovskoy · Woburn, US
Brian Sosa · Cambridge, US

Key dates

Filing date	Jul 27, 2020
Grant date	Nov 16, 2021
Priority date	—
Expiry date	Jul 27, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.